1 |
Abe T, Oda J, Takizawa Y, Suzuki E, Gejyo F. [Evaluation of serum fibrosis markers in asbestos-exposed workers]. Nihon Kokyuki Gakkai Zasshi. 2008;46(11):875-879
|
2 |
Antje P, Joachim M-Q. Non-invasive biomarkers in pulmonary fibrosis. Respirology 2009;14(6):788-795
DOI
ScienceOn
|
3 |
Fumiko K, Hidefumi H, Hiromi H, Toshibumi K, Tadashi I et al. Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT. Respir Med 2004;98(11):1131-1137
DOI
ScienceOn
|
4 |
Inoue Y, Barker E, Daniloff E, Kohno N, Hiwada K et al. Pulmonary epithelial cell injury and alveolar-capillary permeability in berylliosis. Am J Respir Crit Care Med 1997;156(1):109-115
DOI
ScienceOn
|
5 |
Ishikawa N, Kondo K, Oguri T, Kamitsuna M, Sakurai J et al. Usefulnesss of the modified lavage technique of Bingisser and KL-6 monitoring in a patient with pulmonary alveolar proteinosis. Intern Med 2002;41(5):381-385
DOI
|
6 |
Ishikawa N, Mazur W, Toljamo T, Vuopala K, Ronty M et al. Ageing and long-term smoking affects KL-6 levels in the lung, induced sputum and plasma. BMC Pulm Med 2011;11:22
DOI
ScienceOn
|
7 |
Kawase S, Hattori N, Ishikawa N, Horimasu Y, Fujitaka K et al. Changes in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease. Respir Res 2011;12:97
DOI
|
8 |
Kobayashi H, Kanoh S, Motoyoshi K. Serum surfactant protein-A, but not surfactant protein-D or KL-6, can predict preclinical lung damage induced by smoking. Biomarkers 2008;13(4):385-392
DOI
ScienceOn
|
9 |
Kobayashi J, Kitamura S. KL-6: A serum marker for interstitial pneumonia. Chest 1995;108:311-315
DOI
ScienceOn
|
10 |
Kohno N, Awaya Y, Oyama T, Yamakido M, Akiyama M et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 1993;148(3):637-642
DOI
ScienceOn
|
11 |
Kohno N, Inoue Y, Hamada H, Fujioka S, Fujino S et al. Difference in sero-diagnostic values among KL-6-associated mucins classified as cluster 9. Int J Cancer Suppl 1994;8:81-83
|
12 |
Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pnuemonitis activity: Sialylated carbohydrate antigen KL-6. Chest 1989;96:68-73
DOI
ScienceOn
|
13 |
Ministry of health, labour and welfare(MHLW) of Japan. The Technical Guideline for Preventing Health Impairment of Workers Engaged in the Indium Tin Oxide Handling Processes. 2010
|
14 |
Nakajima M, Manabe T, Niki Y, Matsushima T. Serum KL-6 level as a monitoring marker in a patient with pulmonary alveolar proteinosis. Thorax 1998;53(9):809-811.
DOI
ScienceOn
|
15 |
Nakano M, Omae K, Tanaka A, Hirata M, Michikawa T et al. Causal relationship between indium compound inhalation and effects on the lungs. J Occup Health. 2009;51(6):513-521
DOI
ScienceOn
|
16 |
Ogawa Y, Ishikawa T, Ikeda K, Nakata B, Sawada T et al. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer. Clin Cancer Res 2000;6(10):4069-4072
|
17 |
Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung disease. Am J Respir Crit Care Med 2002;165(3):378-381
DOI
ScienceOn
|
18 |
Okada F, Ando Y, Honda K, Tanoue S, Matsumoto S et al. Comparison of pulmonary CT findings and serum KL-6 levels in patients with cryptogenic organizing pneumonia. Br J Radiol 2009;82(975):212-218
DOI
ScienceOn
|
19 |
Satoh H, Kurishima K, Ishikawa H, Ohtsuka M. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med 2006;260(5): 429-434
DOI
ScienceOn
|
20 |
Takahashi T, Munakata M, Ohtsuka Y, Satoh-Kamachi A, Sato R et al. Serum KL-6 concentrations in dairy farmers. Chest. 2000;118(2):445-450
DOI
ScienceOn
|
21 |
Takahashi T, Takamura K, Sakaue S, Ishii J, Yokouchi H et al. Elevated serum KL-6 concentrations in patients with diabetes mellitus. J Diabetes Complications 2002;16(5):352-358
DOI
ScienceOn
|